Mirum Pharmaceuticals (NASDAQ:MIRM) Announces Earnings Results

Mirum Pharmaceuticals (NASDAQ:MIRM) posted its quarterly earnings data on Wednesday. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.22), Zacks reports. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The business had revenue of $99.41 million for the quarter, compared to analyst estimates of $96.64 million. Mirum Pharmaceuticals updated its FY 2025 guidance to EPS.

Mirum Pharmaceuticals Stock Up 1.1 %

Shares of NASDAQ MIRM traded up $0.54 during midday trading on Friday, reaching $47.52. 64,607 shares of the company’s stock were exchanged, compared to its average volume of 527,628. Mirum Pharmaceuticals has a 52-week low of $23.14 and a 52-week high of $54.23. The stock has a market capitalization of $2.28 billion, a PE ratio of -23.52 and a beta of 0.96. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The business’s fifty day moving average price is $46.84 and its two-hundred day moving average price is $43.35.

Analyst Upgrades and Downgrades

MIRM has been the topic of several analyst reports. HC Wainwright raised their price objective on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a report on Friday. Robert W. Baird raised their price objective on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an “outperform” rating in a report on Thursday. Finally, Citigroup raised their price objective on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $58.20.

Insider Transactions at Mirum Pharmaceuticals

In other news, COO Peter Radovich sold 1,998 shares of Mirum Pharmaceuticals stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $85,554.36. Following the sale, the chief operating officer now directly owns 27,015 shares of the company’s stock, valued at approximately $1,156,782.30. The trade was a 6.89 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Jolanda Howe sold 750 shares of Mirum Pharmaceuticals stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total value of $32,115.00. Following the sale, the senior vice president now directly owns 2,926 shares in the company, valued at approximately $125,291.32. The trade was a 20.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 40,915 shares of company stock valued at $1,897,920. 22.87% of the stock is currently owned by insiders.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.